Legacy Wealth Asset Management LLC Has $339,000 Position in Hologic, Inc. (NASDAQ:HOLX)

Legacy Wealth Asset Management LLC raised its holdings in Hologic, Inc. (NASDAQ:HOLX) by 13.6% in the third quarter, Holdings Channel.com reports. The fund owned 4,158 shares of the medical equipment provider’s stock after acquiring an additional 499 shares during the quarter. Legacy Wealth Asset Management LLC’s holdings in Hologic were worth $339,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Innealta Capital LLC acquired a new stake in shares of Hologic in the 2nd quarter valued at $25,000. Wolff Wiese Magana LLC bought a new stake in shares of Hologic during the 3rd quarter worth about $25,000. iA Global Asset Management Inc. acquired a new position in shares of Hologic during the 1st quarter valued at about $37,000. Sunbelt Securities Inc. bought a new position in shares of Hologic in the 2nd quarter valued at approximately $37,000. Finally, Cranbrook Wealth Management LLC acquired a new stake in Hologic in the 2nd quarter worth approximately $47,000. 94.73% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on HOLX. Stephens reissued an “overweight” rating and issued a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Evercore ISI boosted their target price on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Leerink Partners decreased their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Mizuho lifted their price objective on Hologic from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, October 4th. Finally, Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and decreased their target price for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and an average price target of $87.50.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $80.83 on Friday. The firm has a market capitalization of $18.77 billion, a price-to-earnings ratio of 27.49, a PEG ratio of 2.96 and a beta of 0.98. Hologic, Inc. has a one year low of $64.02 and a one year high of $84.67. The business has a fifty day simple moving average of $80.92 and a 200 day simple moving average of $77.86. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period in the previous year, the business earned $0.93 earnings per share. The company’s quarterly revenue was up 2.7% on a year-over-year basis. Sell-side analysts expect that Hologic, Inc. will post 4.09 EPS for the current year.

Insider Buying and Selling at Hologic

In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the transaction, the insider now directly owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Benjamin Jordan Cohn sold 5,093 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the sale, the insider now owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.